Hikma Pharmaceutical (HKMPF) 32.8800 $HKMPF
Jordan Pharmaceutical Market Study 2015
M2 - Fri Sep 25, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xfhgw/the) has announced the addition of the "The Pharmaceutical Market: Jordan" report to their offering. Overview Of The Pharmaceutical Market In Jordan: We expect that Jordan will continue to provide modest opportunities to research-based pharmaceutical manufacturers. In line with the authorities' efforts to expand healthcare insurance coverage , we envisage measures aiming to promote the use of cheaper generic medicines, in tandem with price-reduction strategies. Nevertheless, the expansion of government provision and the higher uptake of generic medicines will conspire to keep longer term growth steady , boosted by upward volume changes, with the patented drug market to continue to be supported by rising numbers of medical tourists. Risk/Reward Rating: Jordan's composite Pharmaceutical Risk/Reward Ratings score for Q1 remains unchanged in relation to the previous quarter. At 49.9 out of the maximum 100, Jordan is again ranked 10th, out of the 30 markets surveyed in the Middle East and Africa region. Jordan's rewards and risk scores remain evenly balanced, with both components standing firmly above the regional averages. Companies Mentioned - Dar al-Dawa - GlaxoSmithKline - Hikma Pharmaceuticals - Jordanian Pharmaceutical Manufacturing Company (JPM) - Merck & Co - Novartis - Pfizer - Pharma International Company - Sanofi - United Pharmaceutical Manufacturers For more information visit http://www.researchandmarkets.com/research/5xfhgw/the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MRK: 50.95 (-0.07), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
Saudi Arabia Pharmaceutical Market Overview 2015
M2 - Thu Sep 24, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3rdslv/the) has announced the addition of the "The Pharmaceutical Market: Saudi Arabia" report to their offering. Saudi Arabia' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs . The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forecasts across our three headline indicators. Risk/Reward Rating: Saudi Arabia's composite score remained steady in Q4 at 55.6. This places the country to firth place out of the 30 markets in the region. Its score is propped up by the country's wealth and a sizeable population (exceeding 28mn). Furthermore, its forecast growth rate is high due to favourable public and private healthcare investments. The government is also in the process of creating more public-private health partnerships and encouraging private health insurance uptake, which should provide momentum for drug sales. Competitive Landscape: The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Company Profiles - SPIMACO - Saudi Arabian Japanese Pharmaceutical (SAJA) - TABUK Pharmaceutical Manufacturing - Jamjoom Pharma - GlaxoSmithKline - Novartis - Merck & Co - Pfizer - Sanofi - Hikma Pharmaceuticals Plc For more information visit http://www.researchandmarkets.com/research/3rdslv/the
MRK: 50.95 (-0.07), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
Lower Respiratory Tract Infections Market Analysis 2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Aug 06, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/396bfs/lower_respiratory) has announced the addition of the "Lower Respiratory Tract Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment" report to their offering. Lower Respiratory Tract Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Reasons to buy - Evaluate the marketing status and exclusivity details of Lower Respiratory Tract Infections key products to exploit opportunities for generic drug development opportunities. - Identify and understand important and diverse types of therapeutics under Phase III development for Lower Respiratory Tract Infections. - Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Lower Respiratory Tract Infections. - API intelligence over marketed drugs for Lower Respiratory Tract Infections and gaining primary intelligence over active ingredients manufacturers across the globe. - API intelligence over leading Phase III pipeline drugs. - Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope. - Understanding the scope of the Phase III Drugs with nil regulatory filings. - Understanding the chemical route of synthesis of approved drugs for Lower Respiratory Tract Infections. - Uncovering opportunities in the rapidly growing the US markets. Companies Mentioned - Merck & Co., Inc. - Dr. Reddy's Laboratories Limited - Corden Pharma International GmbH - Eli Lilly and Company - Genentech, Inc. - Arbor Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Mayne Pharma Limited - Hospira, Inc. - B. Braun Medical Inc. - Bayer Inc. - Actavis, Inc. - Hikma Pharmaceuticals PLC - Sandoz Inc. - Mutual Pharmaceutical Company, Inc. - Par Pharmaceutical Companies, Inc. - GlaxoSmithKline plc - Covis Pharmaceuticals, Inc - Pfizer Inc. - Sanofi - sanofi-aventis U.S. LLC. - King Pharmaceuticals Ltd - Pharmacia & Upjohn, Inc. - AstraZeneca PLC - Astellas Pharma US, Inc. - Baxter Healthcare Corporation - Abraxis BioScience, Inc. - GlaxoSmithKline Inc. - Wyeth Pharmaceuticals, Inc. - GlaxoSmithKline LLC - Warner Chilcott Plc - Wockhardt USA LLC - Hoffmann-La Roche Inc. - Dr. Reddy's Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/39...espiratory
ACT: 298.98 (-2.94), PFE: 33.24 (+0.15), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), MRK: 50.95 (-0.07), AZN: 32.23 (-0.16)
United States General Anesthesia Drugs Market 2015 - Molecule, Route of Administration, Supply Chain & Competitive Analysis to 2020
PR Newswire Europe - Wed Aug 05, 11:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr6xj9/u_s_general [http://www.researchandmarkets.com/research/vr6xj9/u_s_general]) has announced the addition of the "U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020 [http://www.researchandmarkets.com/research/vr6xj9/u_s_general)]" report to their offering.
ABT: 41.89 (+0.73), BAX: 33.21 (-0.04), AZN: 32.23 (-0.16)
U.S. General Anesthesia Drugs Market 2015 by Molecule, Route of Administration, Supply Chain & Competitive Analysis - Forecast to 2020
M2 - Wed Aug 05, 7:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/spz77t/u_s_general) has announced the addition of the "U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s( ) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020" report to their offering. The U.S. general anesthesia drugs market is poised to reach USD 2.0 Billion by 2020 from USD 1.6 Billion in 2015, at a CAGR of 3.8% from 2015 to 2020. Factors such as rapid rise in aging population, rising prevalence of cardiovascular and respiratory system-related diseases, and rising number of emergency surgeries are key factors driving the growth of the U.S. general anesthesia drugs market. However, side effects associated with ketamine usage (such as elevation in blood pressure and heart rate, amnesia, respiratory depression, and hallucinations), regulatory issues, and lower compliance rates in comparison with other anesthetic drugs are likely to restrain the growth of this market. The U.S. general anesthesia drugs market is segmented on the basis of molecule and route of administration. On the basis of molecule, the market is segmented into Propofol, Benzodiazepine, Ketamine (S-( )-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action. On the basis of route of administration, the U.S. general anesthesia drugs market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of the market. Key players operating in the U.S. general anesthesia drugs market are AstraZeneca plc (U.K.), Baxter International Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Eisai Co., Ltd. (Japan), Fresenius Se & Co. KGaA (Germany), Hospira, Inc. (U.S.), and Par Pharmaceutical Companies, Inc. (U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Market Overview 4 Distribution Structure 5 Product Analysis 6 U.S. General Anesthesia Drugs Market: Key Information 7 Strategic Recommendations for Entering the U.S. General Anesthesia Drugs Market 8 Company Profiles - Abbott Laboratories - Astrazeneca PLC - Baxter International Inc. - Eisai Co., Ltd. - Fresenius Se & Co. Kgaa - Hikma Pharmaceuticals PLC - Hospira, Inc. - Mylan N.V. - Par Pharmaceutical Companies, Inc. For more information visit http://www.researchandmarkets.com/research/sp..._s_general
ABT: 41.89 (+0.73), BAX: 33.21 (-0.04), AZN: 32.23 (-0.16)
Hikma Founder and Honorary Life President Samih Darwazah Passes Away
PR Newswire Europe - Mon May 18, 7:06AM CDT
LONDON, May 18, 2015 /PRNewswire/ --
Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Full Year 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 11, 12:51PM CDT
Abortion Market Analysis 2014-2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Tue Jan 13, 9:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/mf3fgc/abortion_market) has announced the addition of the "Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Pharmacia Limited - Pfizer Inc. - Danco Laboratories, LLC - Hikma Pharmaceuticals PLC - Novartis Pharmaceuticals Corporation - APP Pharmaceuticals, Inc. - Solvay Pharma Inc. - Grifols, S.A. For more information visit http://www.researchandmarkets.com/research/mf...ion_market
PFE: 33.24 (+0.15), NVS: 91.90 (-0.71)
Hikma to Launch Colchicine 0.6mg Capsules
PR Newswire Europe - Fri Jan 09, 5:12PM CST
LONDON, January 9, 2015 /PRNewswire/ --
Hikma Pharmaceuticals Announces it Received a Warning Letter from Federal Regulators Over Significant Issues Discovered at Portugal Plant, Parker Waichman LLP Comments
PRWeb - Thu Nov 13, 11:04AM CST
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medications, comments on an October 24, 2014 Hikma Pharmaceuticals' announcement that the multinational pharmaceutical group received a Warning Letter from the U.S. Food and Drug Administration (FDA) concerning an inspection that took place at its Portugal manufacturing facility in March 2014.
Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors
Marketwired - Tue Oct 21, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company appointed Ronald Goode and Jeffrey Lewis to the Board of Directors.
Abscess Market Analysis 2014-2015: API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xv2wdj/abscess_market) has announced the addition of the "Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Abscess Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Pfizer Inc. - Astellas Pharma Inc. - B. Braun Medical Inc. - Actavis, Inc. - Hospira, Inc. - Hikma Pharmaceuticals PLC - Sandoz Inc. - Mutual Pharmaceutical Company, Inc. - Par Pharmaceutical Companies, Inc. - Pharmacia & Upjohn, Inc. - Mission Pharmacal Company - Baxter Healthcare Corporation - Abbott Laboratories - B. Braun Avitum AG - LNK International Inc. For more information visit http://www.researchandmarkets.com/research/xv...ess_market
ABT: 41.89 (+0.73), ACT: 298.98 (-2.94), PFE: 33.24 (+0.15)
Jordan Pharmaceutical Market Study 2015
M2 - Fri Sep 25, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xfhgw/the) has announced the addition of the "The Pharmaceutical Market: Jordan" report to their offering. Overview Of The Pharmaceutical Market In Jordan: We expect that Jordan will continue to provide modest opportunities to research-based pharmaceutical manufacturers. In line with the authorities' efforts to expand healthcare insurance coverage , we envisage measures aiming to promote the use of cheaper generic medicines, in tandem with price-reduction strategies. Nevertheless, the expansion of government provision and the higher uptake of generic medicines will conspire to keep longer term growth steady , boosted by upward volume changes, with the patented drug market to continue to be supported by rising numbers of medical tourists. Risk/Reward Rating: Jordan's composite Pharmaceutical Risk/Reward Ratings score for Q1 remains unchanged in relation to the previous quarter. At 49.9 out of the maximum 100, Jordan is again ranked 10th, out of the 30 markets surveyed in the Middle East and Africa region. Jordan's rewards and risk scores remain evenly balanced, with both components standing firmly above the regional averages. Companies Mentioned - Dar al-Dawa - GlaxoSmithKline - Hikma Pharmaceuticals - Jordanian Pharmaceutical Manufacturing Company (JPM) - Merck & Co - Novartis - Pfizer - Pharma International Company - Sanofi - United Pharmaceutical Manufacturers For more information visit http://www.researchandmarkets.com/research/5xfhgw/the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MRK: 50.95 (-0.07), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
Saudi Arabia Pharmaceutical Market Overview 2015
M2 - Thu Sep 24, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3rdslv/the) has announced the addition of the "The Pharmaceutical Market: Saudi Arabia" report to their offering. Saudi Arabia' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs . The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forecasts across our three headline indicators. Risk/Reward Rating: Saudi Arabia's composite score remained steady in Q4 at 55.6. This places the country to firth place out of the 30 markets in the region. Its score is propped up by the country's wealth and a sizeable population (exceeding 28mn). Furthermore, its forecast growth rate is high due to favourable public and private healthcare investments. The government is also in the process of creating more public-private health partnerships and encouraging private health insurance uptake, which should provide momentum for drug sales. Competitive Landscape: The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Company Profiles - SPIMACO - Saudi Arabian Japanese Pharmaceutical (SAJA) - TABUK Pharmaceutical Manufacturing - Jamjoom Pharma - GlaxoSmithKline - Novartis - Merck & Co - Pfizer - Sanofi - Hikma Pharmaceuticals Plc For more information visit http://www.researchandmarkets.com/research/3rdslv/the
MRK: 50.95 (-0.07), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
Lower Respiratory Tract Infections Market Analysis 2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Aug 06, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/396bfs/lower_respiratory) has announced the addition of the "Lower Respiratory Tract Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment" report to their offering. Lower Respiratory Tract Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Reasons to buy - Evaluate the marketing status and exclusivity details of Lower Respiratory Tract Infections key products to exploit opportunities for generic drug development opportunities. - Identify and understand important and diverse types of therapeutics under Phase III development for Lower Respiratory Tract Infections. - Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Lower Respiratory Tract Infections. - API intelligence over marketed drugs for Lower Respiratory Tract Infections and gaining primary intelligence over active ingredients manufacturers across the globe. - API intelligence over leading Phase III pipeline drugs. - Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope. - Understanding the scope of the Phase III Drugs with nil regulatory filings. - Understanding the chemical route of synthesis of approved drugs for Lower Respiratory Tract Infections. - Uncovering opportunities in the rapidly growing the US markets. Companies Mentioned - Merck & Co., Inc. - Dr. Reddy's Laboratories Limited - Corden Pharma International GmbH - Eli Lilly and Company - Genentech, Inc. - Arbor Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Mayne Pharma Limited - Hospira, Inc. - B. Braun Medical Inc. - Bayer Inc. - Actavis, Inc. - Hikma Pharmaceuticals PLC - Sandoz Inc. - Mutual Pharmaceutical Company, Inc. - Par Pharmaceutical Companies, Inc. - GlaxoSmithKline plc - Covis Pharmaceuticals, Inc - Pfizer Inc. - Sanofi - sanofi-aventis U.S. LLC. - King Pharmaceuticals Ltd - Pharmacia & Upjohn, Inc. - AstraZeneca PLC - Astellas Pharma US, Inc. - Baxter Healthcare Corporation - Abraxis BioScience, Inc. - GlaxoSmithKline Inc. - Wyeth Pharmaceuticals, Inc. - GlaxoSmithKline LLC - Warner Chilcott Plc - Wockhardt USA LLC - Hoffmann-La Roche Inc. - Dr. Reddy's Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/39...espiratory
ACT: 298.98 (-2.94), PFE: 33.24 (+0.15), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), MRK: 50.95 (-0.07), AZN: 32.23 (-0.16)
United States General Anesthesia Drugs Market 2015 - Molecule, Route of Administration, Supply Chain & Competitive Analysis to 2020
PR Newswire Europe - Wed Aug 05, 11:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr6xj9/u_s_general [http://www.researchandmarkets.com/research/vr6xj9/u_s_general]) has announced the addition of the "U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020 [http://www.researchandmarkets.com/research/vr6xj9/u_s_general)]" report to their offering.
ABT: 41.89 (+0.73), BAX: 33.21 (-0.04), AZN: 32.23 (-0.16)
U.S. General Anesthesia Drugs Market 2015 by Molecule, Route of Administration, Supply Chain & Competitive Analysis - Forecast to 2020
M2 - Wed Aug 05, 7:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/spz77t/u_s_general) has announced the addition of the "U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s( ) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020" report to their offering. The U.S. general anesthesia drugs market is poised to reach USD 2.0 Billion by 2020 from USD 1.6 Billion in 2015, at a CAGR of 3.8% from 2015 to 2020. Factors such as rapid rise in aging population, rising prevalence of cardiovascular and respiratory system-related diseases, and rising number of emergency surgeries are key factors driving the growth of the U.S. general anesthesia drugs market. However, side effects associated with ketamine usage (such as elevation in blood pressure and heart rate, amnesia, respiratory depression, and hallucinations), regulatory issues, and lower compliance rates in comparison with other anesthetic drugs are likely to restrain the growth of this market. The U.S. general anesthesia drugs market is segmented on the basis of molecule and route of administration. On the basis of molecule, the market is segmented into Propofol, Benzodiazepine, Ketamine (S-( )-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action. On the basis of route of administration, the U.S. general anesthesia drugs market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of the market. Key players operating in the U.S. general anesthesia drugs market are AstraZeneca plc (U.K.), Baxter International Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Eisai Co., Ltd. (Japan), Fresenius Se & Co. KGaA (Germany), Hospira, Inc. (U.S.), and Par Pharmaceutical Companies, Inc. (U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Market Overview 4 Distribution Structure 5 Product Analysis 6 U.S. General Anesthesia Drugs Market: Key Information 7 Strategic Recommendations for Entering the U.S. General Anesthesia Drugs Market 8 Company Profiles - Abbott Laboratories - Astrazeneca PLC - Baxter International Inc. - Eisai Co., Ltd. - Fresenius Se & Co. Kgaa - Hikma Pharmaceuticals PLC - Hospira, Inc. - Mylan N.V. - Par Pharmaceutical Companies, Inc. For more information visit http://www.researchandmarkets.com/research/sp..._s_general
ABT: 41.89 (+0.73), BAX: 33.21 (-0.04), AZN: 32.23 (-0.16)
Hikma Founder and Honorary Life President Samih Darwazah Passes Away
PR Newswire Europe - Mon May 18, 7:06AM CDT
LONDON, May 18, 2015 /PRNewswire/ --
Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Full Year 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 11, 12:51PM CDT
Abortion Market Analysis 2014-2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Tue Jan 13, 9:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/mf3fgc/abortion_market) has announced the addition of the "Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Pharmacia Limited - Pfizer Inc. - Danco Laboratories, LLC - Hikma Pharmaceuticals PLC - Novartis Pharmaceuticals Corporation - APP Pharmaceuticals, Inc. - Solvay Pharma Inc. - Grifols, S.A. For more information visit http://www.researchandmarkets.com/research/mf...ion_market
PFE: 33.24 (+0.15), NVS: 91.90 (-0.71)
Hikma to Launch Colchicine 0.6mg Capsules
PR Newswire Europe - Fri Jan 09, 5:12PM CST
LONDON, January 9, 2015 /PRNewswire/ --
Hikma Pharmaceuticals Announces it Received a Warning Letter from Federal Regulators Over Significant Issues Discovered at Portugal Plant, Parker Waichman LLP Comments
PRWeb - Thu Nov 13, 11:04AM CST
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medications, comments on an October 24, 2014 Hikma Pharmaceuticals' announcement that the multinational pharmaceutical group received a Warning Letter from the U.S. Food and Drug Administration (FDA) concerning an inspection that took place at its Portugal manufacturing facility in March 2014.
Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors
Marketwired - Tue Oct 21, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company appointed Ronald Goode and Jeffrey Lewis to the Board of Directors.
Abscess Market Analysis 2014-2015: API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xv2wdj/abscess_market) has announced the addition of the "Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Abscess Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Pfizer Inc. - Astellas Pharma Inc. - B. Braun Medical Inc. - Actavis, Inc. - Hospira, Inc. - Hikma Pharmaceuticals PLC - Sandoz Inc. - Mutual Pharmaceutical Company, Inc. - Par Pharmaceutical Companies, Inc. - Pharmacia & Upjohn, Inc. - Mission Pharmacal Company - Baxter Healthcare Corporation - Abbott Laboratories - B. Braun Avitum AG - LNK International Inc. For more information visit http://www.researchandmarkets.com/research/xv...ess_market
ABT: 41.89 (+0.73), ACT: 298.98 (-2.94), PFE: 33.24 (+0.15)
